Stock Analysts’ Upgrades for August, 8th (AAON, ACIA, ACRS, AER, AMRN, AMSC, AMSSY, ARQL, ATHX, ATRO)

Stock Analysts’ upgrades for Wednesday, August 8th:

AAON (NASDAQ:AAON) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $43.00 price target on the stock. According to Zacks, “Aaon Inc. is a manufacturer of air-conditioning and heating equipment consisting of rooftop units, chillers, air-handling units, condensing units and coils. Its products serve the new construction and replacement markets. The Company has successfully gained market share through its semi-custom product lines, which offer the customer value, quality, function, serviceability and efficiency. “

Acacia Communications (NASDAQ:ACIA) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $42.00 target price on the stock. According to Zacks, “Acacia Communications, Inc. designs, develops, manufactures and markets communication equipments. The Company offers coherent optical interconnect products for cloud infrastructure operators and content and communication service providers. It operates primarily in the Americas, Europe, the Middle East, Africa and the Asia Pacific region. Acacia Communications, Inc. is headquartered in Maynard, Massachusetts. “

Aclaris Therapeutics (NASDAQ:ACRS) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $19.00 price target on the stock. According to Zacks, “Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. Its drug candidate consists of A-101, a high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis a common non-malignant skin tumor and A-102, a proprietary topical gel dosage form of hydrogen peroxide for the treatment of SK and common warts which are in different clinical trial. Aclaris Therapeutics, Inc. is headquartered in Malvern, Pennsylvania. “

AerCap (NYSE:AER) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $65.00 price target on the stock. According to Zacks, “AERCAP HOLDINGS is an integrated global aviation company with a leading market position in aircraft and engine leasing, trading and parts sales.They also provides aircraft management services and performs aircraft and engine maintenance, repair and overhaul services and aircraft disassemblies through its certified repair stations. “

Amarin (NASDAQ:AMRN) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Amarin Corporation plc is a global pharmaceutical group which develops innovative pharmaceutical products across a range of therapeutic areas utilizing its proprietary advanced oral and transdermal drug delivery technologies. “

American Superconductor (NASDAQ:AMSC) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “American Superconductor Corporation is a leading energy technologies company. The company develops and sells a wide range of products and solutions based on power electronic systems and high temperature superconductor wires that dramatically improve the efficiency, reliability and quality of electricity during its generation, transmission, distribution and use. The company is a dominant force in alternative energy, offering grid interconnection solutions as well as licensed wind energy designs and electrical systems. As the world’s principal supplier of HTS wire, AMSC is enabling a new generation of compact, high-power electrical products, including power cables, grid-level surge protectors, motors, generators, and advanced transportation and defense systems. AMSC also provides utility and industrial customers worldwide with voltage regulation systems that dramatically enhance power grid capacity, reliability and security, as well as industrial productivity. “

AMS AG/ADR (OTCMKTS:AMSSY) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “ams AG designs, manufactures and sells solutions for consumer electronics and communication device. Its product includes intelligent light sensors, MEMS microphone ICs, NFC solutions, active noise-cancelling ICs and ultra-low power solutions. ams AG is headquartered in Unterpremst├Ątten, Austria. “

ArQule (NASDAQ:ARQL) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $6.25 target price on the stock. According to Zacks, “ArQule, Inc. is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company’s targeted, broad-spectrum products and research programs are focused on key biological processes that are central to cancer. ArQule’s lead clinical-stage products have been generated from two scientific platforms: Cancer Survival Protein modulation and Activated Checkpoint Therapy. The Cancer Survival Protein modulation platform has generated a clinical-stage product that mediates its effects by inhibiting the activity of a molecule known as c-Met, which plays multiple roles in cancer cell growth, survival, invasion, angiogenesis and metastasis. The ACT platform is designed to kill cancer cells selectively while sparing normal cells through direct activation of DNA damage response/checkpoint pathways. The Company’s lead ACT program, based on the E2F-1 pathway, is partnered with Roche. “

Athersys (NASDAQ:ATHX) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Athersys is a biopharmaceutical company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The company’s lead product candidate, ATHX-105, is an oral, selective 5HT2c receptor agonist in Phase I clinical trials for the treatment of obesity. The company is also developing other orally active pharmaceutical product candidates for the treatment of metabolic and central nervous system disorders, utilizing proprietary technologies, including Random Activation of Gene Expression (RAGE). Athersys is developing MultiStem(r), its patented, adult-derived “off the shelf” stem cell product platform, for multiple disease indications, including damage caused by myocardial infarction, bone marrow transplantation/oncology support, ischemic stroke and other indications. “

Astronics (NASDAQ:ATRO) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Astronics Corporation is a manufacturer of specialized lighting and electronics for the cockpit, cabin and exteriors of military, commercial transport and private business jet aircraft. A major lighting and electronics supplier to the aircraft industry, its strategy is to expand from a components and subsystems supplier to an aircraft lighting systems integrator, increasing the value and content it provides to various aircraft platforms. Luminescent Systems Inc. is Astronics’ primary operating subsidiary which produces its aerospace and defense products. “

AngloGold Ashanti (NYSE:AU) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “AngloGold Limited is the largest gold producer at 7 million ounces a year, with reserves of 126 m oz. The company has operations in six countries on three continents, some of which are joint ventures, as well as exploration activities in ten countries. AngloGold can be financially characterized by high cash generation, substantial reinvestment in long-term growth and the payment of significant dividends. The company distinguishes itself from its producer peer group through its active involvement in the development of the gold market, particularly in Asia. “

Taseko Mines (NYSEAMERICAN:TGB) (TSE:TKO) was upgraded by analysts at TD Securities from a hold rating to a buy rating.

Verizon Communications (NYSE:VZ) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $59.00 price target on the stock. According to Zacks, “Verizon reported strong second-quarter 2018 results, beating top- & bottom-line estimates. The company expects healthy improvement in margins on the back of strong FiOS fiber-optic network and strategic services in the Wireline business. Verizon is likely to achieve growth and profitability with a focus on gaining share in the retail post-paid market, increasing penetration of smartphones, and selling more Internet devices such as tablets. Verizon plans to launch next-generation 5G wireless residential broadband services in three to five U.S. markets in 2018. At the same time, Verizon is systematically diversifying itself as a major player in the digital content and online advertising space. The stock has outperformed the industry in the past year on an average. However, the company continues to struggle in a highly competitive and saturated wireless market, where spectrum crunch has become a major issue.”

Wayfair (NYSE:W) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Wayfair's second-quarter revenues were driven by strong direct retail business across the United States and international regions. Further growing numbers of orders from new as well as repeated customers indicates the strong performance of the company. The company stays confident about growth in markets, namely, Canada, U.K. and Germany as the company has made efforts to expand its house-brand offerings in these countries. Additionally, the launch of French language site and CastleGate facility in Canada remains positive. However, increasing advertising expenditures and mounting investment expenses pose a risk to margin expansion. Notably, the stock has outperformed the industry it belongs to in the past 12 months.”

William Lyon Homes (NYSE:WLH) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “William Lyon Homes is primarily engaged in the design, construction, marketing and sale of single-family detached and attached homes in California, Arizona, Nevada and Colorado. The Company conducts its homebuilding operations through five reportable operating segments: Southern California, Northern California, Arizona, Nevada and Colorado through the Village Homes brand. William Lyon Homes is headquartered in Newport Beach, California. “

West Pharmaceutical Services (NYSE:WST) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $129.00 target price on the stock. According to Zacks, “West Pharmaceutical Services, Inc. is a global drug delivery technology company that applies proprietary materials science, formulation research and manufacturing innovation to advance the quality, therapeutic value, development speed and rapid market availability of pharmaceuticals, biologics, vaccines and consumer healthcare products. West is the world’s premiere provider of standard-setting systems and device components for parenterally administered medicines and an emerging leader in the development of advanced formulation technologies for the transmucosal delivery of drugs. West contract manufacturing harnesses a powerful combination of innovation, technology, infrastructure and expertise to serve the pharmaceutical, medical and consumer industries. Along with more than 50 years of experience, they bring customers quality, safety and reliability in injection molding, contract assembly and finished packaging. “

The Western Union (NYSE:WU) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “The Western Union Company’s second-quarter earnings missed the Zacks Consensus Estimate and declined 8% year over year due to weak performances by the Business Solutions and Other segments. Its Consumer to Consumer segment remains attractive and investment in technology bodes well for growth. A strong balance sheet position and accretion from business improvement initiatives are the other positives. Its International business also holds promise. Western Union’s stock has underperformed the industry in a year’s time. Its Business Solutions unit has been underperforming, creating a drag on revenues. The company has been facing high compliance-related and restructuring charges, which weigh on its margins. The company is faced with a number of global economic headwinds, including foreign exchange volatility weakness in some of the economies, which have been limiting its profitability.”

Alleghany (NYSE:Y) was upgraded by analysts at Zacks Investment Research from a hold rating to a strong-buy rating. Zacks Investment Research currently has $734.00 target price on the stock. According to Zacks, “Alleghany’s strong performance across insurance and reinsurance operations will continue to boost its premium revenues. It strives to grow via both acquisitions and organic means as these not only diversify and strengthen its portfolio but also expand its global footprint. A solid balance sheet supports the company’s shareholder-friendly moves and its growth initiatives. It continues to expect compound book value per share growth of 7-10% over a long term. But exposure to cat loss induces volatility in underwriting results while rising expenses weigh on the margin expansion. Shares of Alleghany have underperformed the industry in a year’s time. With respect to quarterly results, Alleghany’s second-quarter 2018 earnings beat the Zacks Consensus Estimate and also improved year over year.”

Receive News & Ratings for AAON Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AAON Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply